Importer of Controlled Substances Application: Actavis Pharma, Inc., 32315-32316 [2014-12976]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 107 / Wednesday, June 4, 2014 / Notices
2 The Title of the Form/Collection:
Notice of Entry of Appearance as
Attorney or Representative Before the
Board of Immigration Appeals.
3 The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
The form number is EOIR–27, Executive
Office for Immigration Review, United
States Department of Justice.
4 Affected public who will be asked or
required to respond, as well as a brief
abstract: Primary: Attorneys or
representatives notifying the Board of
Immigration Appeals (Board) that they
are representing a party in proceedings
before the Board. Other: None. Abstract:
This information collection is necessary
to allow an attorney or representative to
notify the Board that he or she is
representing a party before the Board.
5 An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 26,544
respondents will complete the form
annually with an average of 6 minutes
per response.
6 An estimate of the total public
burden (in hours) associated with the
collection: The estimated public burden
associated with this collection is 2,654
hours. It is estimated that respondents
will take 6 minutes to complete the
form.
If additional information is required
contact: Jerri Murray, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE., 3E.405B,
Washington, DC 20530.
Dated: May 29, 2014.
Jerri Murray,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2014–12835 Filed 6–3–14; 8:45 am]
BILLING CODE 4410–30–P
DEPARTMENT OF JUSTICE
[OMB Number 1125–0006]
tkelley on DSK3SPTVN1PROD with NOTICES
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Notice of
Entry of Appearance as Attorney or
Representative Before the Immigration
Court
Overview of This information
collection:
Executive Office for
Immigration Review, Department of
Justice.
ACTION: 60-Day notice.
AGENCY:
The Department of Justice
(DOJ), Executive Office for Immigration
SUMMARY:
VerDate Mar<15>2010
16:05 Jun 03, 2014
Jkt 232001
Review (EOIR), will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection is published to
obtain comments from the public and
affected agencies.
DATES: Comments are encouraged and
will be accepted for 60 days until
August 4, 2014.
FOR FURTHER INFORMATION CONTACT: If
you have comments, especially on the
estimated public burden or associated
response time, suggestions, or need a
copy of the proposed information
collection instrument with instructions
or additional information, please
contact Jeff Rosenblum, General
Counsel, Executive Office for
Immigration Review, U.S. Department of
Justice, Suite 2600, 5107 Leesburg Pike,
Falls Church, Virginia, 20530;
telephone: (703) 305–0470.
SUPPLEMENTARY INFORMATION: This
process is conducted in accordance with
5 CFR 1320.10. Written comments and
suggestions from the public and affected
agencies concerning the proposed
collection of information are
encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Executive Office for
Immigration Review, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
Attorney or Representative Before the
Immigration Court.
3 The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
The form number is EOIR–28, Executive
Office for Immigration Review, United
States Department of Justice.
4 Affected public who will be asked or
required to respond, as well as a brief
abstract:
Primary: Attorneys and qualified
representatives notifying the
Immigration Court that they are
representing an alien in immigration
proceedings. Other: None. Abstract:
This information collection is necessary
to allow an attorney or representative to
notify the Immigration Court that he or
she is representing an alien before the
Immigration Court.
5 An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: It is estimated that 179,856
respondents will complete the form
annually with an average of 6 minutes
per response.
6 An estimate of the total public
burden (in hours) associated with the
collection: The estimated public burden
associated with this collection is 17,985
hours. It is estimated that respondents
will take six minutes to complete the
form.
If additional information is required
contact: Jerri Murray, Department
Clearance Officer, United States
Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE., 3E.405B,
Washington, DC 20530.
Dated: May 29, 2014.
Jerri Murray,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2014–12836 Filed 6–3–14; 8:45 am]
BILLING CODE 4410–30–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Actavis Pharma, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before July 7, 2014. Such persons
DATES:
1 Type of Information Collection:
Revision and extension of a currently
approved collection.
2 The Title of the Form/Collection:
Notice of Entry of Appearance as
32315
E:\FR\FM\04JNN1.SGM
04JNN1
32316
Federal Register / Vol. 79, No. 107 / Wednesday, June 4, 2014 / Notices
may also file a written request for a
hearing on the application pursuant to
21 CFR 1301.43 on or before July 7,
2014.
DEPARTMENT OF JUSTICE
appropriate. 72 FR 3417 (January 25,
2007).
Drug Enforcement Administration
[Docket No. DEA–392]
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152.
Importer of Controlled Substances
Application: Penick Corporation
Dated: May 28, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014–12962 Filed 6–3–14; 8:45 am]
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, and
dispensers of controlled substances
(other than final orders in connection
with suspension, denial, or revocation
of registration) has been redelegated to
the Deputy Assistant Administrator of
the DEA Office of Diversion Control
(‘‘Deputy Assistant Administrator’’)
pursuant to sec. 7(g) of 28 CFR part 0,
subpart R, App.
In accordance with 21 CFR
1301.34(a), this is notice that on March
20, 2014, Actavis Pharma, Inc., 2455
Wardlow Road, Corona, California
92880–2882, applied to be registered as
an importer of the following basic
classes of controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Schedule
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
II
II
II
II
tkelley on DSK3SPTVN1PROD with NOTICES
The company plans to import the
listed controlled substances for
analytical testing and clinical trials.
The import of the above listed basic
classes of controlled substances will be
granted only for analytical testing and
clinical trials. This authorization does
not extend to the import of a finished
Food and Drug Administration
approved or non-approved dosage form
for commercial distribution in the
United States.
Dated: May 28, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014–12976 Filed 6–3–14; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
16:05 Jun 03, 2014
Jkt 232001
ACTION:
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before July 7, 2014. Such persons
may also file a written request for a
hearing on the application pursuant to
21 CFR 1301.43 on or before July 7,
2014.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, and
dispensers of controlled substances
(other than final orders in connection
with suspension, denial, or revocation
of registration) has been redelegated to
the Deputy Assistant Administrator of
the DEA Office of Diversion Control
(‘‘Deputy Assistant Administrator’’)
pursuant to sec. 7(g) of 28 CFR part 0,
subpart R, App.
In accordance with 21 CFR
1301.34(a), this is notice that on
February 26, 2014, Penick Corporation,
33 Industrial Park Road, Pennsville,
New Jersey 08070, applied to be
registered as an importer of the
following basic classes of controlled
substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
Schedule
II
II
The company plans to import the
listed controlled substances to
manufacture bulk controlled substance
intermediates for sale to its customers.
Comments and requests for any
hearings on applications to import
narcotic raw material are not
PO 00000
BILLING CODE 4410–09–P
Notice of application.
Frm 00104
Fmt 4703
Sfmt 4703
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Application: Mylan Technologies, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration in
accordance with 21 CFR 1301.34(a) on
or before July 7, 2014. Such persons
may also file a written request for a
hearing on the application pursuant to
21 CFR 1301.43 on or before July 7,
2014.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/ODW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, and
dispensers of controlled substances
(other than final orders in connection
with suspension, denial, or revocation
of registration) has been redelegated to
the Deputy Assistant Administrator of
the DEA Office of Diversion Control
(‘‘Deputy Assistant Administrator’’)
pursuant to sec. 7(g) of 28 CFR pt. 0,
subpt. R, App.
In accordance with 21 CFR
1301.34(a), this is notice that on
December 12, 2013, Mylan
Technologies, Inc., 110 Lake Street,
Saint Albans, Vermont 05478, applied
to be registered as an importer of the
following basic classes of controlled
substances:
DATES:
Controlled Substance
Methylphenidate (1724) ................
E:\FR\FM\04JNN1.SGM
04JNN1
Schedule
II
]]>Agencies
[Federal Register Volume 79, Number 107 (Wednesday, June 4, 2014)]
[Notices]
[Pages 32315-32316]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-12976]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Importer of Controlled Substances Application: Actavis Pharma,
Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration in accordance with 21 CFR
1301.34(a) on or before July 7, 2014. Such persons
[[Page 32316]]
may also file a written request for a hearing on the application
pursuant to 21 CFR 1301.43 on or before July 7, 2014.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/ODW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, and dispensers of controlled substances
(other than final orders in connection with suspension, denial, or
revocation of registration) has been redelegated to the Deputy
Assistant Administrator of the DEA Office of Diversion Control
(``Deputy Assistant Administrator'') pursuant to sec. 7(g) of 28 CFR
part 0, subpart R, App.
In accordance with 21 CFR 1301.34(a), this is notice that on March
20, 2014, Actavis Pharma, Inc., 2455 Wardlow Road, Corona, California
92880-2882, applied to be registered as an importer of the following
basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Schedule
------------------------------------------------------------------------
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
analytical testing and clinical trials.
The import of the above listed basic classes of controlled
substances will be granted only for analytical testing and clinical
trials. This authorization does not extend to the import of a finished
Food and Drug Administration approved or non-approved dosage form for
commercial distribution in the United States.
Dated: May 28, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-12976 Filed 6-3-14; 8:45 am]
BILLING CODE 4410-09-P
